IBF

Ayala is looking to lead the way for the country’s burgeoning biotech sector and take its gamma secretase inhibitors all the way through to Phase III.

Ayala entered into an option to license agreement with Novartis for its investigational agent AL102 in multiple myeloma.

The financing and due diligence were led by Israel Biotech Fund and Harel Insurance & Finance Group, with participation of Celgene Corporation, (NASDAQ: CELG), the Japanese-Israeli fund, SBI JI Innovation Fund and existing investors.

Israel Biotech Fund identified the opportunity, led the due diligence and syndicated with aMoon and Harel Insurance in 2017 to form Ayala. Read the full Article

Israel Biotech Fund participated in Gamida Cell’s $40MM financing round which shall support the ongoing Phase 3 trial of the its FDA Breakthrough Designated clinical-stage product, NiCord, to facilitate bone marrow transplantation. Read the full Article

American Association for Cancer Research (AACR) Bestows 2017 Team Science Award to a Renowned Team of Investigators who Pioneered the Science of Liquid Biopsy: Luis A. Diaz, Nishant Agrawazl, Chetan Bettegowda, Frank Diehl, Peter Gibbs, Stanley R. Hamilton, Ralph H. Hruban, Hartmut Juhl, Isaac Kinde, Kenneth Kinzler, Martin Nowak, Nickolas Papadopoulos, David Sidransky, Jeanne Tie, Victor E. Velculescu, Bert Vogelstein Israel Biotech … …

A $30MM funding round in Pharma Two B was led by Israel Biotech Fund, which  syndicated the investment with leading US and Israeli investors. Read the full Article

Israel Biotech Fund, founded to make investments in the Israeli biotech industry, today selected cancer drug developer Vidac for its first investment.Read the full Article

Biogen invests in a newly formed fund dedicated to investment in Israeli and Israeli related biotech companies.Read the full Article